查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
数位生物标誌物市场规模、份额和趋势分析报告：按类型（可穿戴设备、移动应用、传感器）、临床实践、治疗领域、用途、地区、细分市场、2022-2030预测
市场调查报告书
商品编码
1147557

数位生物标誌物市场规模、份额和趋势分析报告：按类型（可穿戴设备、移动应用、传感器）、临床实践、治疗领域、用途、地区、细分市场、2022-2030预测

Digital Biomarkers Market Size, Share & Trends Analysis Report By Type (Wearable, Mobile based Applications, Sensors), By Clinical Practice, By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

数位生物标誌物市场增长和趋势

根据 Grand View Research, Inc. 的最新报告，到 2030 年，全球数字生物标誌物市场规模预计将达到 139.6616 亿美元，预测期内的复合年增长率为 21.9%。由于最近的进步和对远程技术的日益接受，数位生物标记物的市场预计将在整个预测期内扩大。可穿戴和移动技术的进步推动了构成数字生物标记市场最大部分的远程数据收集技术的发展。此外，互联网的日益普及进一步推动了这一细分市场。

特别是语音数位生物标誌物最近出现并具有巨大的商业潜力。可以通过录音、手机和可穿戴设备等患者自有技术轻鬆收集数据。语音生物标誌物有可能通过加强对身体或精神疾病的早期干预和预先识别，从而在预测期内促进市场扩张，从而减轻医疗保健系统的负担并改善患者的治疗效果。

此外，玩家也开始探索语音数位生物标誌物，以在预测期内获得市场占有率并进一步增加收入市场份额。例如，2021 年 10 月，Sonde Health 宣布推出支持语音的心理健康监测技术平台。

此外，由于慢性病和神经退行性疾□□病的患病率上升以及对加强药物开发以成功控制这些疾病的需求不断增加，市场在预测期内将显着增长。与传统的临床试验过程不同，数字生物标誌物可以加速新药开发。

根据分散式临床试验平台提供商之一 Medable 的一项研究，85.0% 的所有临床试验都经历了某种延迟，每天的经济影响在 60 万美元到 800 万美元之间。据说分散式临床试验最多可将 2 期试验时间缩短 1-3 个月。因此，製药商正在投资 DCT 数字生物标誌物，这有望推动市场扩张。例如，2022 年 3 月，阿斯利康宣布向总部位于英国的 HUMA 投资 3300 万美元，该公司提供基于远程数字生物标誌物的分散式临床试验。这种伙伴关係将加速 DCT 的采用。

以远见为导向的市场进入者扩大他们的决策，以加强他们在全球数字生物标誌物市场的地位，利用他们未来成功所需的技术能力和服务的广度。我们正在超越典型的供应商。这些公司采取了多种战略，包括产品发布、合资企业和併购。例如，2022 年 4 月，辉瑞公司宣布收购 ResApp，这是一家总部位于澳大利亚的初创公司，该公司使用人工智能创建了一款应用程序，该应用程序使用患者的咳嗽声音来衡量和确定呼吸系统问题的严重程度。

数位生物标誌物市场报告要点

心血管和代谢疾病 (CVMD) 将在 2021 年占治疗领域部分的最高收入份额，超过 20.0%，随着全球患者人群中心血管疾病的患病率上升。因此，预计将继续成为未来的主要参与者。另一方面，由于 COVID-19 和新兴技术，呼吸系统疾病市场收入份额预计在预测期内以最快的速度增长

诊断数字生物标誌物在 2021 年占临床实践部分的最大收入份额，原因是越来越多地使用用于临床疾病和日常生活的诊断监测。此外，用于监测的数字生物标誌物有望在预测期内实现最快的收入增长

由于尖端的可穿戴智能手錶等新产品的推出，2021 年可穿戴设备在数字生物标记类型细分市场中的收入份额超过 39.0%。由于全球智能手机的广泛使用，基于移动的应用程序的收入份额预计将在预测期内以最快的速度增长。此外，新技术和传感器的使用越来越多，预计将在预测期内产生激烈的竞争。

由于适应症的增加以及对具有成本效益的临床试验和产品分析策略的需求增加，医疗保健公司在 2021 年的最终用途类别中占据了超过 50.0% 的最大市场份额。

由于其完善的先进医疗基础设施和研发活动的大量支出，北美将在 2021 年占据市场主导地位，占总收入的份额超过 59.0%。此外，欧洲将在预测期内表现出最快的增长

主要参与者还通过合作伙伴关係、收购、合併和产品发布为市场的扩张做出贡献。例如，在 2021 年，Medable 将与数字生物标誌物公司 Aural Analytics 合作，测量远处的言语模式并监测健康状况和衰退阶段

内容

第 1 章调查方法及范围

  • 市场细分和范围
  • 调查方法
  • 资讯采购
    • 购买的数据库：
    • GVR 内部数据库
    • 次要资讯
    • 初步调查
    • 初步调查的内容
  • 资讯或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 模型详细资讯
    • 商品流分析（模型 1）
      • 方法 1：商品流方法
  • 二级资讯列表
  • 主要资讯列表
  • 报告的目的

第 2 章执行摘要

  • 市场展望
  • 2021 年数位生物标誌物市场概览

第 3 章数位生物标誌物市场变量、趋势和范围

  • 市场系列展望
    • 母公司市场展望
    • 辅助市场展望
  • 描绘渗透率和增长前景
  • 数位生物标誌物市场动态
    • 市场促进因素分析
      • 远程技术的最新创新和日益普及
      • 智能手机使用率的增加和新型可穿戴设备的出现
      • 扩大治疗范围
      • 增加对分散式临床试验的投资
    • 市场抑制因素分析
      • 数据隐私问题
      • 缺乏对新兴经济学的认识和熟练的专业人员
  • 数位生物标誌物市场分析工具：波特五力分析
    • 供应商的力量
    • 买家的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的敌对关係
  • PESTEL 分析
    • 政治和法律格局
    • 社交情况
    • 技术概况
    • 环境分析
  • 监管框架
  • 技术概览
  • 价格分析
  • COVID-19 影响分析
    • 当前和未来的影响分析
    • COVID-19 对市场参与者的影响

第 4 章竞争格局

  • 市场参与分类
  • 上市公司
    • 公司市场分析
    • 协同分析：主要交易和战略联盟
  • 市场参与者的详细列表

第 5 章数位生物标誌物市场：细分分析，按类型，2017-2030（百万美元）

  • 类型变化分析，2021 年和 2030 年
    • 可穿戴设备
    • 基于移动的应用程序
    • 传感器
    • 其他

第 6 章数位生物标誌物市场：细分分析，按临床实践，2017-2030（百万美元）

  • 2021 年和 2030 年临床实践变化分析
    • 诊断数位生物标誌物
    • 监测数位生物标誌物
    • 预测和预后数位生物标誌物
    • 其他

第 7 章。数位生物标誌物市场：细分分析，按治疗领域，2017-2030 年（百万美元）

  • 治疗变异分析，2021 年和 2030 年
    • 心血管和代谢紊乱 (CVMD)
    • 呼吸系统疾病
    • 精神障碍
    • 睡眠和运动疾病
    • 神经系统疾病
    • 肌肉骨骼疾病
    • 其他

第 8 章数位生物标誌物市场：细分分析，按最终用途，2017-2030（百万美元）

  • 2021 年和 2030 年最终用途变化分析
    • 医疗保健公司
    • 医疗保健提供者
    • 付款人
    • 其他

第 9 章数位生物标誌物市场：按类型、临床实践、治疗领域和最终用途（百万美元）分列的区域市场分析，2017-2030

  • 2017-2030 年市场规模、预测、数量和趋势分析
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 荷兰
    • 意大利
    • 瑞士
  • 亚太地区
    • 日本
    • 中国
    • 澳大利亚
    • 印度
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
  • 多边环境协定
    • 南非
    • 以色列

第 10 章公司简介

  • ActiGraph LLC
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • AliveCor Inc
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Koneksa
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Amgen Inc.
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Biogen Inc.
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Altoida Inc
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • IXICO plc
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Adherium Limited
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Empatica Inc
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Huma
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • VivoSense
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • ResApp（Pfizer）
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
Product Code: GVR-4-68039-989-3

Digital Biomarkers Market Growth & Trends:

The global digital biomarkers market size is expected to reach USD 13,966.16 million by 2030, registering a CAGR of 21.9% during the forecast period, according to a new report by Grand View Research, Inc. Due to the rising acceptance of recent advancements and remote technologies, the market for digital biomarkers is anticipated to expand throughout the forecast period. Development of the remote data collecting technologies, which make up the largest segment of the market for digital biomarkers, has been propelled by the improvements in wearable and mobile technology. Additionally, this market segment is being further assisted by the growing use of the internet.

Vocal digital biomarkers in particular have lately come into existence and offer enormous business development potential. They enable easy data collection through voice recordings and through patient-owned technology like cell phones, wearables, and other devices. Vocal biomarkers are being utilized more frequently, which might ease the strain on the healthcare systems and improve patient outcomes by enhancing early intervention and before-time identification of physical or mental illnesses, boosting the market's expansion during the forecast period.

Furthermore, in order to acquire market presence and further boost its revenue market share during the forecast, players have also begun exploring the vocal digital biomarkers. For instance, in October 2021, Sonde health launched a voice-enabled mental fitness monitoring technology platform.

Additionally, the market is anticipated to experience substantial expansion during the forecast period due to the rising prevalence of chronic diseases and neurodegenerative diseases, as well as the growing need for enhanced drug development to successfully control these diseases. In comparison to the conventional clinical trial process, digital biomarkers accelerate the development of new drugs.

According to a study by one of the well-known decentralized trial platform providers, Med able, 85.0% of all clinical trials experience some sort of delay, with the financial impact of delays costing between USD 600,000 and USD 8 million per day, decentralized clinical trials could save up to 1 to 3 months of time in phase 2 studies. As a result, medicine manufacturers are spending money on a digital biomarker for DCT, which is anticipated to fuel market expansion. For instance, AstraZeneca stated in March 2022 that it had invested USD 33.0 million in Huma, a UK-based company that provides decentralized clinical trials based on remote digital biomarkers. Through this alliance, the company will quicken the adoption of DCT.

Forward-thinking market participants are expanding their decisions and moving beyond typical suppliers in order to strengthen the company's position in the global market for digital biomarkers by utilizing the wide range of technology capabilities and services required for future success. These companies have employed a variety of strategies such as product launches, joint ventures, and mergers & acquisitions. For instance, in April 2022, Pfizer acquired ResApp, an Australian- based startup that had created an app that uses artificial intelligence to gauge and determine the severity of respiratory problems using the coughing voice of a patient.

Digital Biomarkers Market Report Highlights:

  • Cardiovascular and metabolic disorders (CVMD) had the highest revenue share of more than 20.0% in the therapeutic area segment in 2021 and is anticipated that it will continue to have a significant major presence given the rising prevalence of cardiovascular diseases among patient populations around the globe. On the other hand, due to COVID-19 and emerging new technologies, it is anticipated that during the forecast period, market revenue share for respiratory disorders will expand at the fastest rate
  • Due to the growing use of diagnostic monitoring meant for clinical disease and daily living, diagnostic digital biomarkers had the largest revenue share in the clinical practice segment in 2021. Moreover, the fastest revenue growth is anticipated for monitoring digital biomarkers during the forecast period
  • Wearable had a revenue share of more than 39.0% in the digital biomarker type segment in 2021, due to the release of new, cutting-edge wearable smart watches and other products. As a result of the extensive usage of smartphones, worldwide, it is anticipated that revenue share growth for mobile-based applications would happen at the fastest rate during the forecast period. Additionally, rising usage of new technologies, and sensors, would also confront intense competition during the forecast period
  • Healthcare companies hold the largest, more than 50.0% market share within the end-use category, in 2021, as a result of the rising indications and demands for cost-effective clinical trial and product analysis strategies
  • North America dominated the market in 2021 and generated more than 59.0% share of the total revenue, as a result of its well-established advanced healthcare infrastructure and large expenditure in R&D activities. Furthermore, Europe would see the fastest rate of growth during the forecast period
  • By engaging in partnerships, acquisitions, mergers, and product launches, key companies also help the market to expand. For instance, in 2021, Med able collaborated with the digital biomarkers business Aural Analytics to measure distant speech patterns and monitor their well-being and stage of decline

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
  • 1.9 Report Objectives

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Digital BiomarkersMarket Summary, 2021

Chapter 3 Digital Biomarkers Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Digital Biomarkers Market Dynamics
    • 3.3.1 Market Driver Analysis
      • 3.3.1.1 Increased Popularity of Recent Innovations and Remote Technologies
      • 3.3.1.2 Rising Usage of Smartphones and The Emergence of New Wearables
      • 3.3.1.3 Expanding Therapeutic Area Application
      • 3.3.1.4 Increasing Investment in Decentralized Clinical Trials
    • 3.3.2 Market Restraints Analysis
      • 3.3.2.1 Concerns about Data Privacy
      • 3.3.2.1 Lack of Awareness and Poor Skilled Professionals in Emerging Economics
  • 3.4 Digital Biomarkers Market Analysis Tools: Porter's Five Forces Analysis
    • 3.4.1 Supplier Power
    • 3.4.2 Buyer Power
    • 3.4.3 Threat Of Substitutes
    • 3.4.4 Threat Of New Entrants
    • 3.4.5 Competitive Rivalry
  • 3.5 Pestel Analysis
    • 3.5.1 Political & Legal Landscape
    • 3.5.2 Social Landscape
    • 3.5.3 Technology Landscape
    • 3.5.4 Environmental Analysis
  • 3.6 Regulatory Framework
  • 3.7 Technology Overview
  • 3.8 Pricing Analysis
  • 3.9 Covid-19 Impact Analysis
    • 3.9.1 Current And Future Impact Analysis
    • 3.9.2 Impact Of Covid-19 On Market Players

Chapter 4 Competitive Landscape

  • 4.1 Market participation categorization
  • 4.2 Public Companies
    • 4.2.1 Company Market Position Analysis
    • 4.2.2 Synergy Analysis: Major Deals & Strategic Alliances
  • 4.3 Detailed list of market players

Chapter 5 Digital Biomarkers Market: Segment Analysis, by type, 2017 - 2030 (USD Million)

  • 5.1 Type Movement Analysis, 2021 & 2030
    • 5.1.1 Wearable
      • 5.1.1.1 Wearable Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 5.1.2 Mobile Based Applications
      • 5.1.2.1 Mobile Based Applications Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 5.1.3 Sensors
      • 5.1.3.1 Sensors Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 5.1.4 Others
      • 5.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 6 Digital Biomarkers Market: Segment Analysis, by Clinical Practice, 2017 - 2030 (USD Million)

  • 6.1 Clinical Practice Movement Analysis, 2021 & 2030
    • 6.1.1 Diagnostic Digital Biomarkers
      • 6.1.1.1 Diagnostic Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 6.1.2 Monitoring Digital Biomarkers
      • 6.1.2.1 Monitoring Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 6.1.3 Predictive and Prognostic Digital Biomarkers
      • 6.1.3.1 Predictive and Prognostic Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 6.1.4 Others
      • 6.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 7 Digital Biomarkers Market: Segment Analysis, by Therapeutic Area, 2017 - 2030 (USD Million)

  • 7.1 Therapeutic Area Movement Analysis, 2021 & 2030
    • 7.1.1 Cardiovascular and Metabolic Disorders (CVMD)
      • 7.1.1.1 Cardiovascular and Metabolic Disorders (CVMD) Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 7.1.2 Respiratory Disorders
      • 7.1.2.1 Respiratory Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 7.1.3 Psychiatric Disorders
      • 7.1.3.1 Psychiatric Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 7.1.4 Sleep & Movement Disease
      • 7.1.4.1 Sleep & Movement Disease Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 7.1.5 Neurological Disorders
      • 7.1.5.1 Neurological Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 7.1.6 Musculoskeletal Disorders
      • 7.1.6.1 Musculoskeletal Disorders Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 7.1.7 Others
      • 7.1.7.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 8 Digital Biomarkers Market: Segment Analysis, by End-Use, 2017 - 2030 (USD Million)

  • 8.1 End-Use Movement Analysis, 2021 & 2030
    • 8.1.1 Healthcare Companies
      • 8.1.1.1 Healthcare Companies Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 8.1.2 Healthcare Providers
      • 8.1.2.1 Healthcare ProvidersMarket Estimates and Forecasts, 2017 - 2030 (Million)
    • 8.1.3 Payers
      • 8.1.3.1 Payers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 8.1.4 Others
      • 8.1.4.1 Others Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 9 Digital Biomarkers Market: Regional Market Analysis, by type, clinical practice, therapeutic area, and end-Use, 2017 - 2030 (USD Million)

  • 9.1 Market Size, & Forecasts, Volume, and Trend Analysis, 2017 to 2030
  • 9.2 North America
    • 9.2.1 North America Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.2.2 U.S.
      • 9.2.2.1 U.S. Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.2.3 Canada
      • 9.2.3.1 Canada Digital Biomarkers Market Estimates and Forecasts, 2017 -2030 (Million)
  • 9.3 Europe
    • 9.3.1 Europe Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.3.2 U.K.
      • 9.3.2.1 U.K. Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.3.3 Germany
      • 9.3.3.1 Germany Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.3.4 Netherlands
      • 9.3.4.1 Netherlands Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.3.5 Italy
      • 9.3.5.1 Italy Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.3.6 Switzerland
      • 9.3.6.1 Switzerland Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.4.2 Japan
      • 9.4.2.1 Japan Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.4.3 China
      • 9.4.3.1 China Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.4.4 Australia
      • 9.4.4.1 Australia Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.4.5 India
      • 9.4.5.1 India Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.4.6 South Korea
      • 9.4.6.1 South Korea Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.5 Latin America
    • 9.5.1 Latin America Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Brazil Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.5.3 Mexico
      • 9.5.3.1 Mexico Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
  • 9.6 MEA
    • 9.6.1 MEA Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.6.2 South Africa
      • 9.6.2.1 South Africa Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)
    • 9.6.3 Israel
      • 9.6.3.1 Israel Digital Biomarkers Market Estimates and Forecasts, 2017 - 2030 (Million)

Chapter 10 Company Profiles

  • 10.1 ActiGraph LLC
    • 10.1.1 Company Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Benchmarking
    • 10.1.4 Strategic Initiatives
  • 10.2 AliveCor Inc
    • 10.2.1 Company Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Benchmarking
    • 10.2.4 Strategic Initiatives
  • 10.3 Koneksa
    • 10.3.1 Company Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Benchmarking
    • 10.3.4 Strategic Initiatives
  • 10.4 Amgen Inc.
    • 10.4.1 Company Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Benchmarking
    • 10.4.4 Strategic Initiatives
  • 10.5 Biogen Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Benchmarking
    • 10.5.4 Strategic Initiatives
  • 10.6 Altoida Inc
    • 10.6.1 Company Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Benchmarking
    • 10.6.4 Strategic Initiatives
  • 10.7 IXICO plc
    • 10.7.1 Company Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Benchmarking
    • 10.7.4 Strategic Initiatives
  • 10.8 Adherium Limited
    • 10.8.1 Company Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Benchmarking
    • 10.8.4 Strategic Initiatives
  • 10.9 Empatica Inc
    • 10.9.1 Company Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Benchmarking
    • 10.9.4 Strategic Initiatives
  • 10.10 Huma
    • 10.10.1 Company Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Benchmarking
    • 10.10.4 Strategic Initiatives
  • 10.11 VivoSense
    • 10.11.1 Company Overview
    • 10.11.2 Financial Performance
    • 10.11.3 Product Benchmarking
    • 10.11.4 Strategic Initiatives
  • 10.12 ResApp (Pfizer)
    • 10.12.1 Company Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Benchmarking
    • 10.12.4 Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of key companies
  • Table 3. North America Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
  • Table 4. North America Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 5. North America Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 6. North America Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 7. North America Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 8. U.S. Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 9. U.S. Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 10. U.S. Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 11. U.S. Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 12. Canada Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 13. Canada Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 14. Canada Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 15. Canada Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 16. Europe Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
  • Table 17. Europe Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 18. Europe Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 19. Europe Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 20. Europe Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 21. U.K. Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 22. U.K. Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 23. U.K. Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 24. U.K. Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 25. Germany Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 26. Germany Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 27. Germany Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 28. Germany Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 29. Netherlands Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 30. Netherlands Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 31. Netherlands Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 32. Netherlands Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 33. Italy Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 34. Italy Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 35. Italy Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 36. Italy Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 37. Switzerland Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 38. Switzerland Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 39. Switzerland Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 40. Switzerland Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 41. Asia Pacific Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
  • Table 42. Asia Pacific Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 43. Asia Pacific Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 44. Asia Pacific Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 45. Asia Pacific Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 46. China Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 47. China Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 48. China Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 49. China Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 50. Japan Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 51. Japan Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 52. Japan Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 53. Japan Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 54. India Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 55. India Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 56. India Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 57. India Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 58. Australia Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 59. Australia Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 60. Australia Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 61. Australia Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 62. South Korea Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 63. South Korea Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 64. South Korea Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 65. South Korea Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 66. LATAM Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
  • Table 67. LATAM Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 68. LATAM Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 69. LATAM Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 70. LATAM Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 71. Brazil Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 72. Brazil Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 73. Brazil Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 74. Brazil Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 75. Mexico Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 76. Mexico Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 77. Mexico Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 78. Mexico Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 79. MEA Digital Biomarkers market, by country, 2017 - 2030 (USD Million)
  • Table 80. MEA Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 81. MEA Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 82. MEA Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 83. MEA Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 84. South Africa Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 85. South Africa Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 86. South Africa Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 87. South Africa Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 88. Israel Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 89. Israel Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 90. Israel Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 91. Israel Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)
  • Table 92. Global Digital Biomarkers market, by region, 2017 - 2030 (USD Million)
  • Table 93. Global Digital Biomarkers market, by type, 2017 - 2030 (USD Million)
  • Table 94. Global Digital Biomarkers market, by clinical practice, 2017 - 2030 (USD Million)
  • Table 95. Global Digital Biomarkers market, by therapeutic area, 2017 - 2030 (USD Million)
  • Table 96. Global Digital Biomarkers market, by end-use, 2017 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD Modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Segment-Based Penetration Model
  • Fig. 11 Market summary (2021, Million)
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Market variable analysis
  • Fig. 14 Market driver relevance analysis (Current & future impact)
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 Digital Biomarkers Market: By Type Movement Analysis, 2021 & 2030
  • Fig. 17 Wearable Market, 2017 - 2030 (Million)
  • Fig. 18 Mobile based Applications Market, 2017 - 2030 (Million)
  • Fig. 19 Sensors Market, 2017 - 2030 (Million)
  • Fig. 20 Others Market, 2017 - 2030 (Million)
  • Fig. 21 Digital Biomarkers Market: By Clinical Practice Movement Analysis, 2021 & 2030
  • Fig. 22 Diagnostic digital biomarkers market, 2017 - 2030 (Million)
  • Fig. 23 Monitoring digital biomarkers market, 2017 - 2030 (Million)
  • Fig. 24 Predictive and Prognostic digital biomarkers market, 2017 - 2030 (Million)
  • Fig. 25 Others digital biomarker market, 2017 - 2030 (Million)
  • Fig. 26 Digital Biomarkers Market: By Therapeutic Area Movement Analysis, 2021 & 2030
  • Fig. 27 Cardiovascular and metabolic disorders (CVMD) market, 2017 - 2030 (Million)
  • Fig. 28 Respiratory disorders market, 2017 - 2030 (Million)
  • Fig. 29 Psychiatric disorders market, 2017 - 2030 (Million)
  • Fig. 30 Sleep & movement disease market, 2017 - 2030 (Million)
  • Fig. 31 Neurological disorders market, 2017 - 2030 (Million)
  • Fig. 32 Musculoskeletal disorders market, 2017 - 2030 (Million)
  • Fig. 33 Others market, 2017 - 2030 (Million)
  • Fig. 34 Digital Biomarkers Market: By End-Use Movement Analysis, 2021 & 2030
  • Fig. 35 Healthcare companies market, 2017 - 2030 (Million)
  • Fig. 36 Healthcare Providers market, 2017 - 2030 (Million)
  • Fig. 37 Payers market, 2017 - 2030 (Million)
  • Fig. 38 Others market, 2017 - 2030 (Million)
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 Regional outlook, 2021 & 2030
  • Fig. 41 North America Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 42 U.S. Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 43 Canada Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 44 Europe Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 45 U.K. Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 46 Germany Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 47 Netherlands Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 48 Italy Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 49 Switzerland Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 50 Asia Pacific Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 51 Japan Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 52 China Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 53 India Digital Biomarkers Market, 2017- 2030 (Million)
  • Fig. 54 South Korea Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 55 Australia Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 56 Latin America Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 57 Brazil Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 58 Mexico Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 59 MEA Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 60 South Africa Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 61 Israel Digital Biomarkers Market, 2017 - 2030 (Million)
  • Fig. 62 Market Participation Categorization
  • Fig. 63 Company market position analysis